weekly_roundup

BioTechSign Daily Catalyst Roundup - November 18, 2026

Top BioTechSign catalyst names today: UCBNV, EIKN, ZBIO, CMPX, MLTX, BAYRY. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 18, 2026

Daily Biotech Catalyst Digest: November 18, 2026

UCBNV leads the current BioTechSign screen at 100.0/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
UCBNVUCB SA100.0Aclinical activity 100%
EIKNEikon Therapeutics, Inc.85.5Apublication signal 100%, clinical activity 100%, short interest 70%
ZBIOZenas BioPharma, Inc.81.5Aclinical activity 100%, short interest 70%, publication signal 35%
CMPXCompass Therapeutics, Inc.81.1Aclinical activity 92%, short interest 90%, publication signal 60%
MLTXMoonLake Immunotherapeutics80.5Aclinical activity 100%, short interest 50%, publication signal 35%
BAYRYBayer AG79.5Bpublication signal 100%, clinical activity 100%, dilution risk 40%

Recent Grade-Change Queue

  • NCEL (NewcelX Ltd.) currently grades F with a 14.5/100 catalyst score. Main inputs: dilution risk 62%, short interest 10%, publication signal 5%.
  • JAZZ (Jazz Pharmaceuticals plc) currently grades D with a 45.6/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, PDUFA timing 35%.
  • RZLT (Rezolute, Inc.) currently grades D with a 38.2/100 catalyst score. Main inputs: short interest 70%, dilution risk 62%, clinical activity 50%.
  • PBYI (Puma Biotechnology Inc) currently grades C with a 56.5/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 50%.
  • UCBNV (UCB SA) currently grades A with a 100.0/100 catalyst score. Main inputs: clinical activity 100%.
  • SNY (Sanofi SA) currently grades B with a 73.3/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, dilution risk 12%.
  • EYPT (EyePoint, Inc.) currently grades D with a 47.5/100 catalyst score. Main inputs: short interest 50%, dilution risk 47%, publication signal 40%.
  • EXEL (Exelixis Inc) currently grades B with a 76.0/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 50%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.